In a report released today, Sam Slutsky from LifeSci Capital maintained a Hold rating on InflaRx (IFRX – Research Report). The company’s shares ...

Investment analysts at Lifesci Capital issued their Q1 2025 EPS estimates for Protara Therapeutics in a note issued to investors on Tuesday, March 11th. Lifesci Capital analyst C. Zhu expects that the ...

Liquidia Co. (NASDAQ:LQDA – Free Report) – Equities research analysts at Lifesci Capital issued their Q2 2025 earnings estimates for shares of Liquidia in a report issued on Wednesday ...

Fintel reports that on March 12, 2025, LifeSci Capital initiated coverage of Monte Rosa Therapeutics (NasdaqGS:GLUE) with a Outperform recommendation. Analyst Price Forecast Suggests 145.23% Upside As ...

Fintel reports that on March 11, 2025, LifeSci Capital initiated coverage of Immunome (NasdaqCM:IMNM) with a Outperform recommendation. Analyst Price Forecast Suggests 250.92% Upside As of March 4 ...

LifeSci Capital analyst Charles Zhu initiated coverage with a Buy rating on Zymeworks (ZYME – Research Report) today and set a price target of $30.00. The company’s shares clo ...

Fintel reports that on March 12, 2025, LifeSci Capital initiated coverage of Monte Rosa Therapeutics (NasdaqGS:GLUE) with a Outperform recommendation. As of March 4, 2025, the average one-year ...